A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
SL Rogers, MR Farlow, RS Doody, R Mohs… - Neurology, 1998 - AAN Enterprises
The efficacy and safety of donepezil as a treatment for patients with mild to moderate
Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. Patients
were randomly assigned to treatment with placebo (n= 162), 5 mg/d donepezil (n= 154), or
10 mg/d donepezil (n= 157) for 24 weeks followed by a 6-week, single-blind placebo
washout. The primary efficacy measures were the cognitive portion of the Alzheimer's
Disease Assessment Scale (ADAS-cog) and the Clinician's Interview Based Assessment of …
Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. Patients
were randomly assigned to treatment with placebo (n= 162), 5 mg/d donepezil (n= 154), or
10 mg/d donepezil (n= 157) for 24 weeks followed by a 6-week, single-blind placebo
washout. The primary efficacy measures were the cognitive portion of the Alzheimer's
Disease Assessment Scale (ADAS-cog) and the Clinician's Interview Based Assessment of …
A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study
VP Prasher, A Huxley, MS Haque… - … Journal of Geriatric …, 2002 - Wiley Online Library
Abstract Background Donepezil Hydrochloride (Aricept) is a selective anticholinesterase
inhibitor developed for the treatment of Alzheimer's disease (AD). This study investigated the
safety and efficacy of the drug to treat Down syndrome (DS) adults with mild to moderate AD.
Method This was a 24‐week, double blind, placebo controlled, parallel‐group trial. Patients
were randomized to receive placebo or donepezil (5 mg per day during the first four weeks,
and then 10 mg per day thereafter). Primary efficacy was measured using the Dementia …
inhibitor developed for the treatment of Alzheimer's disease (AD). This study investigated the
safety and efficacy of the drug to treat Down syndrome (DS) adults with mild to moderate AD.
Method This was a 24‐week, double blind, placebo controlled, parallel‐group trial. Patients
were randomized to receive placebo or donepezil (5 mg per day during the first four weeks,
and then 10 mg per day thereafter). Primary efficacy was measured using the Dementia …